The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved GSK plc’s (NYSE:GSK) Penmenvy (Meningococcal Groups A, B, C, W, and Y ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

The shot mixes the antigenic components of GSK’s established meningococcal vaccines Bexsero and Menveo, which target MenB and MenACWY, respectively, to offer broader coverage in fewer doses.

Pfizer's MenABCWY shot – which combines its MenACWY vaccine Nimenrix with and MenB jab Trumenba – will now be filed for FDA approval in adolescents and young adults in the fourth quarter of ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

NHS England said the ‘potential’ introduction of a varicella vaccine could be launched in January 2026, subject to ‘final ...

MenB vaccines are unique in terms of their potential strain coverage and adverse event profile. Meningococcal vaccine implementation can be influenced by public and political forces. Given these ...

GSK has garnered FDA approval for its pentavalent meningococcal vaccine Penmenvy, tipped as one of its major launches for 2025 and a rival to Pfizer's first-to-market Penbraya.

The US Food and Drug Administration (FDA) has approved GSK’s pentavalent meningococcal vaccine, Penmenvy, for children and ...

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.